Review on Formulation and Evaluation of Immediate Release tablets of Bedaquiline

Bedaquiline, an anti-tubercular agent used in the treatment of multidrug-resistant tuberculosis (MDR-TB). Due to its low aqueous solubility and poor bioavailability, formulation development focused on enhancing the dissolution rate of bedaquiline to achieve rapid therapeutic action. Tablets were prepared using wet granulation method, employing various solubility-enhancing excipients such as surfactants and disintegrants. The prepared formulation was evaluated for precompression parameters, including bulk density, tapped density, and flow properties, as well as postcompression parameters such as hardness, friability, weight variation, disintegration time, and in-vitro drug release profiles. The optimized formulation exhibited a disintegration time of less than 3 minutes and a drug release of over 85% within 30 minutes, confirming its suitability for immediate -release purposes. Compatibility studies using Fouriertransform infrared (FTIR) spectroscopy indicated no significant interactions between bedaquiline and excipients. Stability studies conducted as per ICH guidelines revealed no significant changes in physical or chemical properties, ensuring the formulation's robustness. The findings suggest that the formulated immediate-release bedaquiline tablets are a promising strategy to improve patient compliance and achieve rapid therapeutic efficacy in MDR-TB treatment.